Ebb Therapeutics, the medical device innovator of Ebb Insomnia Therapy, has selected The Copley Consulting Group to facilitate and deploy Infor’s CloudSuite Industrial (SyteLine) solution. With the first and only FDA-cleared device that reduces the time it takes insomnia patients to fall asleep and enter deeper sleep, Ebb is anticipating significant growth as it prepares […]Read More +
Congratulations to Copley Customer and Infor SyteLine user, Quanterix who was recently nominated as one of BostInno’s “50 on Fire” awards in healthcare and medicine for 2015. Only five of the 21 companies nominated will win, but all of them are having an impact in the hub of the healthcare universe.
Quanterix manufactures a device that measures the tiniest concentrations of proteins in the blood, detecting diseases and injuries ranging from cancer to Alzheimers to concussions. Its latest application is in sports fitness, testing for proteins typically found in spinal fluid to measure whether someone has had a concussion.
Quanterix received a $500,000 grant from GE and the NFL to search for these telltale biomarkers. Its CEO and chairman, Kevin Hruvosky, estimates that sales of reagents it manufactures for testing, combined with sales of its $150,000 device and licensing of its diagnostic technology, could propel Quanterix to $150 million in revenue within five years. With that in mind, Hruvosky says he’s preparing for an eventual IPO.
The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant commercial unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more.
For the full list of nominees click here